Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China
- 18 July 2012
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 84 (9) , 1408-1414
- https://doi.org/10.1002/jmv.23325
Abstract
Human adenoviruses have been used to develop candidate HIV vaccine vectors, but a major obstacle to the use of vectors derived from Ad5 and other common serotypes is the high prevalence of neutralizing antibodies (NAbs) in humans. Prior studies have reported a prevalence of Ad5 between 60% and 70% in Europe and US, and up to 98% in surveyed African and Asian (Thai) tropical countries. However, few studies have reported on the Ad5 prevalence in Chinese populations. In this study, a total of 1,250 healthy adult serum samples from six administratively separate regions of China were screened by high‐throughput luciferase‐based virus neutralization assays. Results showed that overall 72% of healthy adults were Ad5 seropositive, and 46.4% with baseline Ad5 NAb titers of >200 in China. Comprehensive analysis by geographical region and age showed that the seroprevalence of Ad5 in southern China such as Guangxi was higher than that in other regions. Geographical differences and climate were considered as the major factors affecting the titer levels of Ad5 in healthy adults. In addition, no apparent gender and ethnic difference was found in any group classified according to region, age, or NAb titer. The present study may provide useful insights for the future development of Ad5‐based vaccines and gene therapy. J. Med. Virol. 84:1408–1414, 2012.Keywords
This publication has 24 references indexed in Scilit:
- Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cellsNature Medicine, 2009
- Insufficient accumulation of viral late mRNAs restricts the replicative cycle of human adenovirus type 37 in A549 cellsArchiv für die gesamte Virusforschung, 2009
- Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacyVaccine, 2009
- Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade BgagVaccines in Healthy AdultsAIDS Research and Human Retroviruses, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialPublished by Elsevier ,2008
- Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and ImmunotherapyJournal of Virology, 2008
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 VaccinesJournal of Virology, 2003
- Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag GeneJournal of Virology, 2003
- Large Epidemic of Adenovirus Type 4 Infection among Military Trainees: Epidemiological, Clinical, and Laboratory StudiesClinical Infectious Diseases, 2002